GB2234897A - Irrigating fluid for transurethral resections - Google Patents
Irrigating fluid for transurethral resections Download PDFInfo
- Publication number
- GB2234897A GB2234897A GB9017018A GB9017018A GB2234897A GB 2234897 A GB2234897 A GB 2234897A GB 9017018 A GB9017018 A GB 9017018A GB 9017018 A GB9017018 A GB 9017018A GB 2234897 A GB2234897 A GB 2234897A
- Authority
- GB
- United Kingdom
- Prior art keywords
- irrigating fluid
- glycine
- turp
- arginine
- absorption
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
An irrigating fluid particularly suitable for use to transurethral resections comprises an aqueous solution of glycine and L-arginine.
Description
Title: Prophylaxis of Transurethral Resection Reactions
DESCRIPTION
This invention is concerned with prevention and/or treatment of transurethral resection (TUR) reaction or TUR prostate syndrome when glycine solution is used as irrigating fluid.
Irrigating fluid absorption in patients during transurethral resection of prostate is a recognised complication.
When pure water was used for irrigation during transurethral resection, absorption of such water led to hypotonicity and intravascular haemolysis in some patients (Creevy, Journal of Urology 1947).
Nesbit and Glickman (Journal of Urology 1948) recommeded glycine solution to prevent such intravascular haemolysis. Since then, 1.5% w/v glycine solution remains to be the most commonly used irrigating fluid for transurethral resection in most western countries. A three litre bag would contain about EOOm/M of glycine.
Even with the introduction of 1.5% glycine solution, although preventing serious intravascular haemolysis, absorption during transurethral resection could still produce symptoms called TUR-reaction or
TURP-Syndrome (Harrison et al Journal of Urology 1956). Characteristic symptons of TUR-reaction include bradycardia, tachypnoea, restlessness, apprehension, muscular twitching, delayed awakening from general anaesthesia, transient blindness, confusion, convulsion, collapse, coma and death in the worst cases (Wakin, K G et al Journal of Urology 1971, Harrison et al 1956 (above) and Appelt G L et al Journal of
Urology 1979).
Traditionally the solvent fraction of irrigating fluid has been blamed for this reaction. Absorption of the irrigating fluid could produce hyponatraemia and nypervolaemia which have been blamed for TUR-reaction.
As a precaution against such reaction many suggestions came in the literature.
Fillman et al JAMA 1959 suggested limiting the resection to one hour.
Harrison et al (above) made various recommendations. These included limiting the resection time, using low irrigation pressure, not attempting repeated fulguration of venous bleeding, and lastly by leaving a rim of prostatic tissue and not reaching to the capsule until the very end of resection.
Hurlbert et al Anaesthesiology 1979 reported a case of water intoxication following absorption of 1.5% glycine after only 15 minutes of TURP (with absorption of about 6 litres of fluid).
As the attempts to prevent TUR-reaction continued, attentions were also directed towards the system of using irrigating fluid.
Madsen and Naber Journal of Urology 1973(9) stressed the point of hanging the irrigating fluid bag not higher than 60cms above the operating table in order not to raise the pressure in the prostatic fossa and thereby prevent the absorption of irrigating fluid.
Iglesias J J et al Journal of Urology 1975 showed that the volume of irrigating fluid absorption during TURP will be lower if continuous irrigation and suction and resectoscope is used. This system maintained the intravesical pressure below Scms of water, which is lower than the pressure in the pelvic veins.
Stephenson T P et al BJU 1980 did not find any significant difference between the intermittent and continuous suction methods for irrigating fluid absorption or for operating time of TURP.
Rao et al BJU 1983 showed the modification of irrigant supply system. The height of the fluid column was maintained at 15cms above the symphysis pubis and the final bladder pressure was kept around 15cms of water - much lower than existing system. This also kept the flow rate constant.
Recently more attention has been drawn toward the solute fraction of the irrigating fluid.
The effect of absorbed glycine from irrigating fluid was studied by Fitzpatrick et al BJU 1981. They showed high levels of oxalates and glycolates (the metabolic products of glycine) in the urine in patients who also had hyponatraemia.
Zucker and Bull Can. Anaesth. Soc. Journal 1984 showed that the majority of patients (12/17) after TURP with 1.5% glycine used as irrigating fluid, showed more than 100D increase in plasma glycine levels. Only a small number of patients (4/17) had serum sodium dropped by 5-lOmEq/1. They pointed out how inappropriate it was to regard hyponatraemia only as the measure of severity of irrigating fluid absorption.
They stressed the point of measuring glycine in blood as more appropriate of irrigating fluid absorption because 15mls of glycine irrigating fluid absorption would approximately double the plasma glycine concentration i.e. 100S increase, whilst diluting the serum sodium by only 0.1D.
Hoekstra et al Journal of Urology 1983 ascribed three cases of TURP-syndrome characterised by stupor and coma. All three patients had transurethral resection of prostate with glycine as irrigating fluid. Their blood ammonia levels were elevated by more than 10 times the normal level. They all improved when their blood ammonia level came down to normal. In their prospective study, 46% patients developed hyperammonaemia following TURP using 1.5% glycine.
Shepard et al BJU 1987 studied the patients who underwent TURP using 1.5% glycine solution. 38% of them showed hyperammonaemia, 14% of these had developed clinical signs of encephalopathy. They concluded: "There is no specific treatment for hyperammonaemia other than the support of cardiovascular and respiratory function. It can easily be prevented by avoiding the use of 1.5g glycine as a urological irrigant".
Thus, prevention of or at least reducing hyperammonaemia is believed to be one way of eliminating or reducing the effect of TUR-reaction or
TURP syndrome.
It is known from various sources such as Piero
Gullino - Archieves of Biochemistry and Biophysics 1956, J. Fahey - J. Clin Investigation 1957 and
Nathens et al - J. Lab and Clinical Medicine 1958 that
L-arginine has a protective effect against hyperammonaemia in various hosts but no connection between that and preventing TUR reaction or TURPsyndrome has ever been made.
A first ojbect of this invention is to reduce or eliminate TUR-reactions following TURP.
A second object of this invention is to provide a novel irrigating fluid, especially for use in TURP.
A third object of this invention is to provide a method of treating TUR-reactions.
According to the invention it is proposed that Larginine be administered to a patient before, during or after TURP.
In particular, the invention proposes an irrigating fluid, especially for TURP, comprising an aqueous solution of glycine and L-arginine.
L-arginine is preferably included in the irrigating fluid in an amount of upto about 15t preferably upto about 10%, especially from about 5 - 10% of the glycine. The glycine will preferably continue to be used as a 1 to 2, especially 1.5%, w/v solution.
Thus, in specific examples of an irrigating fluid of the invention a 3 litre bag of aqueous irrigating fluid will contain 600m M of glycine and either 60m M or 30m M or L-arginine.
Alternatively, L-arginine may be adminstered separately from surgical procedure, such as by parenteral administration say as a component of protein nutrition supplied intravenously. Such protein nutrition will usually comprise a selection of amino acids and L-arginine may be present in any suitable amount. Amounts upto 10% or even higher, preferably from 5 to 10% by weight of amino acids may be suitable.
It is envisaged that the administration of Larginine to a patient of TURP will prevent or reduce hyperammonaemia and so prevent or reduce effects of TURreaction.
This invention will now be further described with reference to the following examples:
Example 1
An irrigating fluid suitable for use in transurethral reactions was made as a 3 litre bag containing in aqueous solution 600m M of glycine and 60m
M of L-arginine.
Example 2
An irrigating fluid suitable for use in transurethral reactions was made as a 3 litre bad containing in aqueous solution 600m M of glycine and 30m
M of L-arginine.
Claims (7)
1. An irrigating fluid, especially for TURP, comprising an aqueous solution of glycine and Larginine.
2. An irrigating fluid as claimed in claim 1, wherein glycine is present is an amount of from 1 to 2% w/v solution.
3. An irrigating fluid as claimed in claim 2, wherein glycine is present in an amount of 1.5% w/v solution.
4. An irrigating fluid as claimed in claim 1, 2 or 3, wherein L-arginine is present in an amount of upto 15% by weight of the glycine.
5. An irrigating fluid as claimed in claim 4, wherein L-arginine is present in an amount of upto about 10% by weight of the glycine.
6. An irrigating fluid as claimed in claim 4, wherein L-arginine is present in an amount of from 5 to 10% by weight of the glycine.
7. An irrigating fluid as claimed in claim 1 and substantially as hereinbefore described with reference to either of the examples.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB898917660A GB8917660D0 (en) | 1989-08-02 | 1989-08-02 | Prophylaxis of transurethral resection reactions |
Publications (2)
Publication Number | Publication Date |
---|---|
GB9017018D0 GB9017018D0 (en) | 1990-09-19 |
GB2234897A true GB2234897A (en) | 1991-02-20 |
Family
ID=10661048
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB898917660A Pending GB8917660D0 (en) | 1989-08-02 | 1989-08-02 | Prophylaxis of transurethral resection reactions |
GB9017018A Withdrawn GB2234897A (en) | 1989-08-02 | 1990-08-02 | Irrigating fluid for transurethral resections |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB898917660A Pending GB8917660D0 (en) | 1989-08-02 | 1989-08-02 | Prophylaxis of transurethral resection reactions |
Country Status (1)
Country | Link |
---|---|
GB (2) | GB8917660D0 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002078688A1 (en) * | 2001-03-30 | 2002-10-10 | Aga Ab | Irrigating fluid |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2029220A (en) * | 1978-09-04 | 1980-03-19 | Otsuka Pharma Co Ltd | Amino acid solutions for patients with cancers |
US4279917A (en) * | 1978-09-08 | 1981-07-21 | Ajinomoto Company, Incorporated | Amino acid solution for intravenous nutrition |
EP0034504A2 (en) * | 1980-02-19 | 1981-08-26 | Anthony N. Silvetti, Sr. | Combinations for the treatment of wounds |
EP0147682A1 (en) * | 1983-12-05 | 1985-07-10 | Ajinomoto Co., Inc. | Novel amino acid infusion solution |
-
1989
- 1989-08-02 GB GB898917660A patent/GB8917660D0/en active Pending
-
1990
- 1990-08-02 GB GB9017018A patent/GB2234897A/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2029220A (en) * | 1978-09-04 | 1980-03-19 | Otsuka Pharma Co Ltd | Amino acid solutions for patients with cancers |
US4279917A (en) * | 1978-09-08 | 1981-07-21 | Ajinomoto Company, Incorporated | Amino acid solution for intravenous nutrition |
EP0034504A2 (en) * | 1980-02-19 | 1981-08-26 | Anthony N. Silvetti, Sr. | Combinations for the treatment of wounds |
EP0147682A1 (en) * | 1983-12-05 | 1985-07-10 | Ajinomoto Co., Inc. | Novel amino acid infusion solution |
Non-Patent Citations (1)
Title |
---|
Martindale "The Extra Pharmacopoeia", 28th Edition, pages 62-63 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002078688A1 (en) * | 2001-03-30 | 2002-10-10 | Aga Ab | Irrigating fluid |
US7041275B2 (en) | 2001-03-30 | 2006-05-09 | Robert Hahn | Irrigating fluid |
Also Published As
Publication number | Publication date |
---|---|
GB9017018D0 (en) | 1990-09-19 |
GB8917660D0 (en) | 1989-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
McCormack | Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis | |
Gross et al. | Is hypertonic saline resuscitation safe in ‘uncontrolled’hemorrhagic shock? | |
Nelson et al. | Total hip arthroplasty in Jehovah's Witnesses without blood transfusion. | |
Logie et al. | Fluid absorption during transurethral prostatectomy | |
Emmett et al. | Fluid absorption during transurethral resection: comparison of mortality and morbidity after irrigation with water and non-hemolytic solutions | |
Hahn | Transurethral resection syndrome from extravascular absorption of irrigating fluid | |
KR20080041621A (en) | Eye drop preparation comprising xanthan gum and terpenoid | |
JP2024028391A (en) | aqueous ophthalmic composition | |
CN106692120A (en) | Medicine composition of lidocaine and application of medicine composition | |
CN103349776B (en) | Edaravone injection solution and preparation method thereof | |
CHIANG et al. | Dexamethasone and pentastarch produce additive attenuation of ischaemia/reperfusion lung injury | |
Marino et al. | Dilutional hyponatremia during endoscopic curettage: The “female TURP syndrome”? | |
GB2234897A (en) | Irrigating fluid for transurethral resections | |
Bizios et al. | Effects of cyclooxygenase and lipoxygenase inhibition on lung fluid balance after thrombin | |
Aghamir et al. | Sterile water versus isotonic saline solution as irrigation fluid in percutaneous nephrolithotomy | |
Ostfeld et al. | Headache and hydration: the significance of two varieties of fluid accumulation in patients with vascular headache of the migraine type | |
CA2179147A1 (en) | Improved intraocular irrigating solution containing non-steroidal antiinflammatory agent | |
Nilsson et al. | Haemodynamic effects of irrigating fluids studied by Doppler ultrasonography in volunteers | |
CN101380294B (en) | Preparation method of solid dispersion medicine for treating hemorrhage | |
Flechner et al. | Continuous flow and conventional resectoscope methods in transurethral prostatectomy: comparative study | |
CN107349189B (en) | A kind of sorbierite mannitol flushing liquor suitable for urological surgery | |
Premaratne et al. | Significance of oxygen free radicals in the pathophysiology of hemorrhagic shock-a protocol | |
US11406658B2 (en) | Composition comprising glycyrrhizin and cosmetic and pharmaceutical uses thereof | |
CN107536844A (en) | Application of the nicotinamide mononucleotide in the medicine for preparing prevention or treatment rtPA vascular complications | |
George et al. | Incidence, clinical manifestations and outcome of TUR (transurethral resection) syndrome in patients undergoing TURP under spinal anaesthesia: results from clinical observations in a cohort of 50 patients at a tertiary care centre in North India |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |